Characteristics | Value |
---|---|
Median age (range), y | Â |
Adult (n = 65) | 46.9 (18.4 - 83.6) |
Child (n = 3) | 4.8 (2.8 - 5.2) |
Men, n (%) | 47 (69) |
Continent of birth, n (%) | Â |
Europe | 34 (50) |
Africa | 27 (40) |
Other | 7 (10) |
Immunity status*, n (%) | Â |
Non-immune | 39 (57) |
Partially immune | 29 (43) |
Semi immune | 0 (0) |
Chemoprophylaxis, n (%) | Â |
Adequate | 1 (2) |
Inadequate | 58 (85) |
   Absent | 49 (72) |
   Inappropriate | 9 (13) |
Unknown | 9 (13) |
Indication for artesunate, n (%) | Â |
Severe malaria§ (> 1 of the following criteria) | 51 (75) |
Impaired consciousness | 18 (26) |
Multiple convulsions (> 2 episodes/24 h) | 0 (0) |
Respiratory distress or pulmonary edema | 4 (6) |
Shock (systolic blood pressure < 70 mm Hg) | 6 (9) |
Haemoglobinuria | 2 (3) |
Abnormal bleeding | 1 (2) |
Hypoglycaemia (glucose < 2.2. mmol/L) | 1 (2) |
Acidaemia (pH < 7.25) | 3 (4) |
Acidosis (plasma bicarbonate < 15 mmol/L) | 4 (6) |
Anaemia (Hb < 3.1 mmol/l or haematocrit < 15%) | 0 (0) |
Hyperparasitaemia (> 5%) | 33 (49) |
Hyperlactataemia (lactate > 5 mmol/L) | 8 (12) |
Renal impairment (creatinine > 265 μmol/L) | 7 (11) |
Jaundice (bilirubin > 50 μmol/L) | 24 (35) |
Non severe malaria on admission | 17 (25) |
Clinical deterioration to severe malaria | 4 (6) |
Parasitaemia between 2-5% | 4 (6) |
Unable to take oral medication†| 5 (7) |
Other‡ | 4 (6) |